New antibody takes aim at Hard-to-Treat cancers

NCT ID NCT07541001

Ongoing Disease control Sponsor: Intra-IMMUSG Pte Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack the tumor. The study aims to see if the drug can slow cancer growth and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRL3-zumab (an antibody that targets a protein called PRL3 found on cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMOR

Contacts and locations

Locations

Hangzhou Cancer Hospital

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.